Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China
NATICK, Mass. – December 8, 2025 – (PR NEWSWIRE) – Pillar Biosciences announced today an expansion of its existing laboratory access program with AstraZeneca for NGS-based kitted liquid biopsy tumor profiling to include China. This expanded collaboration aims to deliver rapid, cost-effective, and clinically actionable genomic insights through liquid biopsy testing. By increasing the local […]
Pillar Biosciences Announces Final CMS Pricing Determination for oncoReveal® CDx
Natick, Mass. – December 1, 2025 – Pillar Biosciences, the leader in Decision Medicine™, todayannounced that the Centers for Medicare & Medicaid Services (CMS) has finalized its pricingdetermination for oncoReveal CDx. Following its preliminary decision in August 2025, CMSconfirmed a crosswalk-based payment rate of $1,352.09, effective for claims with dates of service onor after January […]
Pillar Biosciences Announce Automated NGS Library Preparation Method on Hamilton Microlab STAR to Accelerate Myeloproliferative Neoplasm Research
NATICK, Mass. and RENO, NV – October 28, 2025 Pillar Biosciences, Inc., and Hamilton Company today announced the validation and release of their first automated NGS library preparation method under their NGS Application Development and Co-Marketing Agreement, for use on Hamilton Microlab® STARTM liquid handling systems. Pillar’s research-use-only (RUO) oncoReveal® Essential MPN, a rapid 3-gene […]
Pillar Biosciences to Showcase NGS Research Insights at 2025 AMP Meeting
NATICK, Mass. – October 23, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, announced its participation in the 2025 Association for Molecular Pathology (AMP) Annual Meeting in Boston, MA. The company and scientific collaborators will collectively present eight studies and host three corporate workshops, showcasing their latest advancements in rapid Next-Generation Sequencing (NGS) […]
Fast, reliable solutions for oncology workflows: Illumina and Pillar team up at ESMO 2025 to showcase a powerful combination of NGS tests
At ESMO 2025, Illumina teams up with Pillar Biosciences to showcase their powerful combination of NGS tests
Pillar Biosciences and Platomics Announce Collaboration to Support EU Clinical Labs with Documentation of NGS Workflows
September 4, 2025 – Pillar Biosciences, Inc., a leading provider of kitted next-generation sequencing (NGS) panels, and regulatory automation provider Platomics are collaborating to streamline compliance for next-generation sequencing (NGS) tests under the EU’s In Vitro Diagnostic Regulation (IVDR). Now that IVDR has come into force, clinical laboratories must provide extensive regulatory documentation. Labs are […]
Pillar Biosciences Raises $34.5M in Funding
May 27, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced they have received $34.5M in funding, including a strategic investment from Illumina, and structured financing from Soleus Capital and investments from existing investors. Proceeds from this financing will be leveraged to advance Pillar’s commercial activities including headcount and infrastructure to support […]
Pillar Biosciences Receives CMS Coverage for FDA Approved oncoReveal® CDx Pan-Cancer Solid tumor IVD Kit
April 3, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced they have received nationwide Medicare coverage by the Centers for Medicare & Medicaid Services (CMS) for oncoReveal® CDx pan-cancer solid tumor in vitro diagnostic (IVD) NGS kit. oncoReveal® CDx is a NGS based IVD kit that uses Pillar’s proprietary SLIMamp (Stem-Loop […]
Pillar Biosciences and Hamilton Company Announce NGS Application Development and Co-Marketing Agreement
Collaboration aims to accelerate automation of rapid NGS testing February 18, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has entered into a strategic NGS automation application development agreement and co-marketing partnership with Hamilton Company. As part of this agreement, Hamilton will develop automation scripts and supporting technical and commercial literature for selected, […]
Reflecting on 2024: A Year of Growth, Innovation, and Partnership at Pillar Biosciences
In 2024, Pillar Biosciences made significant strides in advancing our mission of Decision Medicine™ and improving cancer diagnostics through rapid, innovative Next-Generation Sequencing (NGS) kitted solutions. We’ve made substantial advancements and improved access to precision oncology solutions globally. Here is a summary of select key achievements in 2024: FDA Approval of oncoReveal® CDx In April, Pillar […]